Campath

This page contains recent news articles, when available, and an overview of Campath but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Campath® and Rituxan® Promising for Untreated High-risk CLL  -  Oct 7, 2008
1 Currently, there are two antibodies approved by the US Food and Drug Administration (FDA) for malignancies of B-cell lymphocytes: Rituxan and Campath. Cancer Consultants,

UPDATE 1-Bayer sees opportunity for health M&A  -  Oct 2, 2008
It also has a number of products in development that could become big sellers, including a product known as VEGF-trap for sight loss, Campath for multiple guardian.co.uk,

Streamlining Genmab Cuts 100 Jobs, Drops Pivotal CTCL Drug  -  Oct 8, 2008
In addition to Campath, ofatumumab would face competition from Frazer, Pa.-based Cephalon Inc.'s Treanda (bendamustine HCl), which gained approval in March BioWorld Online,

A Forecast Insight Analysis of the Multiple Sclerosis Market ...  -  Sep 24, 2008
Genzyme and Bayer Scherings alemtuzumab (Campath) has been added to this latest multiple sclerosis forecast. Potentially positioned in both the earliest MarketWatch

Phase III Study of Rituxan in Leukemia Meets its Goal  -  Oct 7, 2008
Other currently available treatments for CLL include the monoclonal antibody Campath (alemtuzumab), which targets the CD52 antigen, and chemotherapy agents BioWorld Online,

Forecast Insight - Multiple Sclerosis - www.companiesandmarkets ...  Sep 12, 2008
Genzyme and Bayer Schering´s alemtuzumab (Campath) has been added to this latest multiple sclerosis forecast. Potentially positioned in both the earliestPR-Inside.com (Pressemitteilung),

Pharmacyclics, Inc. Announces Board and Management Transitions  Sep 11, 2008
...which successfully received approval for a cancer monoclonal antibody CAMPATH, and also had five other cancer drugs in clinical development.MarketWatch

Azaya Therapeutics Licenses Promising Treatment For Head And Neck ...  Sep 5, 2008
...several key executive positions with Ilex Oncology, Inc. and was instrumental in the development and approval of the company's drug, Campath® (alemtuzumab).Medical News Today (press release),

Evestra, Inc. Raises $4.35 Million  Aug 18, 2008
During Shaked's tenure at ILEX, the company won Food and Drug Administration approval for the drug Campath, a treatment for B-cell chronic lymphocyticPharmaLive.com (press release),

MS Market is Estimated to Be Worth Almost US$8 Billion in 2008 ...  Sep 2, 2008
GLOSSARY - MS REFERENCES - ACRONYMNS Key Products Analysed and Forecast: - BG-12 - Biogen Idec - Campath - Bayer - Fingolimod - Novartis - LacquinimodPR-Inside.com (Pressemitteilung),

Diabetes trial nets BTG $7.5m milestone payment  -  07 Aug 2008
...“TRX4 is the third of our licensed programmes to enter phase III trials recently, alongside Campath for MS and abiraterone acetate for prostate cancer, ShareCast,

Bayer "hold"  -  07 Aug 2008
B. rivaroxaban zur Vorbeugung von Venenthromboembolien und Campath bei Multiple Sklerose sowie die Partnerschaft mit dem US-Generikahersteller Barr bzgl. AktienCheck,

GlaxoSmithKline pays $15 million to Tolerx  -  07 Aug 2008
Tolerx Inc. has begun a late-stage human clinical trial for a new diabetes treatment. As a result, development partner GlaxoSmithKline PLC will give the Bizjournals.com,

Genmab, GSK Report Mid-Term Findings for Leukemia Drug  -  Aug 5, 2008
...a partial response in 30 of 59 patients resistant to treatment with fludarabine and Genzyme and Bayer Healthcare’s Campath (alemtuzumab), GenMab said. FDA news (subscription),

Genmab Leukemia Drug Shows Strong Results in Trial  -  Jul 31, 2008
About half of 138 patients involved had previously not responded to two other medications – Campath and the chemotherapy fludarabine. Wall Street Journal

Genmab, Glaxo cancer drug beats target in key test  -  Jul 31, 2008
A second group of patients refractory to fludarabine and for whom Campath was inappropriate because of their bulky tumours, saw an objective response rate Reuters

Genzyme Reaching For a Slice From Biogen’s Breadbasket, Multiple ...  -  Jul 17, 2008
Genzyme (NASDAQ: GENZ) is recruiting patients in two final-stage clinical trials of Campath, currently approved as a leukemia drug, for patients with Xconomy,

5 Stocks Basking in the Summer Sun  -  Jul 17, 2008
Genzyme wants in on the $9 billion market, and it is moving its leukemia drug, Campath, to final clinical tests for patients with MS. Motley Fool

NEW AMERICA  -  Jul 15, 2008
One is Campath, a bone-marrow cancer drug Genzyme is testing for severe forms of multiple sclerosis. The other is Synvisc-One, a single-shot treatment for Investor's Business Daily (subscription)

PTC inks $437M pact with Genzyme  -  Jul 17, 2008
ALSO: Xconomy examines Genzyme's late-stage MS drug Campath, which could go head to head against Biogen Idec's Avonex and Tysabri for the FierceBiotech,

Genzyme Reports Strong Second-Quarter Growth  -  Jul 23, 2008
Oncology revenue rose in the second quarter to $33.3 million from $17.4 million based on increasing sales of Clolar and Campath(R) (alemtuzumab). FOXBusiness

Patsy's MS battle raises £140000 for charity  -  Jul 16, 2008
Patsy, a pupil at Gateshead’s Thomas Hepburn School, became the only person under 18 to try out the trial MS drug Campath. She lives with her parents, ChronicleLive,

Nation's Fourth Hand Transplant Performed at Jewish Hospital Hand ...  -  Jul 12, 2008
..."What is important to note is that our last patient was the first hand recipient in the world to receive a new drug - Campath - to avoid the use of steroids MarketWatch

Biogen: 2 patients get brain disease  -  Jul 31, 2008
...s cancer drug Campath has also been linked to PML. But the concern is especially strong about Tysabri because two patients died when the drug was new and Boston Globe,

Recipient Dave Armstrong talks about hand transplant  -  Jul 24, 2008
During surgery, Ravindra said Armstrong received an injection of Campath, a drug that allows doctors to avoid using steroids to prevent rejection, Louisville Courier-Journal,

Yesterday's trading: BTG boosted by new cancer pill  -  Jul 22, 2008
Campath, its potential treatment for multiple sclerosis and licensed to Genzyme Corporation, commenced phase III trials earlier this year, while TRX4, This is Money,

Genmab/Goldman: Nu kommer investorerne efter Ofatumumab  -  Aug 1, 2008
Desuden er en responsrate på 44 pct. i flurabine-resistente og Campath intolerante patienter samt en patient med komplet respons også meget signifikant. Børsen Online,

GSK 항암제 ‘오파투무맙’ 3�?결과 우수  -  Jul 31, 2008
...오파투무맙�?� 만성림프구성백혈병(CLL) 환�?�? 대한 3�? 임�? 중간결과, '플루다�?�빈'(fludarabine)과 '캄파스'(Campath, alemtuzumab) 치료�? 불�?��?� 환�?�?서 24주뒤 디지틀보사,

BTG plc: Study Shows Abiraterone Can Successfully Treat Aggressive ...  -  Jul 22, 2008
Campath®, licensed to Genzyme Corporation, is already approved to treat chronic lymphocytic leukaemia and is under development as a potential treatment for PharmaLive.com (press release),

Takeda Takes Hold of Millennium for $8.8 Billion  -  Jun 18, 2008
The biotech got hold of its first approved drug, Campath (now owned by Genzyme), and its one currently marketed product, the cancer drug Velcade, Xconomy,

Chancellor presents Honorary Degrees  -  Jun 23, 2008
He is particularly noted for the development of CAMPATH-1H, a monoclonal antibody used in the treatment of chronic lymphocytic leukaemia. Cambridge Network,

UPDATE: BTG Fiscal Year Revenue +60%, Plans To In-License New Drugs  -  May 19, 2008
BTG said the jump in revenue was due to strong sales of marketed products like cancer drug Campath, sold by Genzyme Corp. (GENZ); hemophilia treatment CNNMoney.com

Genzyme rises on prediction of profit growth  -  May 14, 2008
Campath is already on the market as a treatment for a kind of bone marrow cancer, and Porges said it should become the most effective drug for Houston Chronicle,

INTERVIEW BTG to increase late-stage development as announces ...  -  May 19, 2008
...'The answer to that is yes (the cash) certainly could make a major contribution (to running of the business) but remember we've also got Varisolve, Campath Thomson Investment Management News (subscription),

Big Brother star in charity zipslide plunge  -  May 19, 2008
Patsy, now 15, a pupil at Gateshead’s Thomas Hepburn School, became the only person under 18 to try out the trial MS drug Campath. ChronicleLive,

Sector Wrap: Cancer Drug developers  -  May 27, 2008
...s leukemia drug Campath could see a slight decline in sales, but it will be too small to have any impact on the company, Meacham said. CNNMoney.com

Oral Drug From Novartis/Mitsubishi Tanabe Will Capture The  -  May 30, 2008
...and alemtuzumab, which is marketed in the US as Campath for B-cell chronic lymphocytic leukemia by Bayer HealthCare and Genzyme Oncology. Pharmaceutical Online (press release),

'Miracle' helps Kidd fight cancer  -  May 21, 2008
..."I started taking a shot in my stomach it was called campath," said Kidd. Kidd had a rough road of recovery ahead of him as he went through 12 weeks of Altavista,

Genzyme Reports Strong First-Quarter Growth  -  23 Apr 2008
Oncology revenue also reflects growing first-line use of Campath(R) (alemtuzumab) in the treatment of patients with B-cell chronic lymphocytic leukemia. PR Newswire (press release),

Genzyme Reports Strong First-Quarter Growth  -  23 Apr 2008
Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are CNNMoney.com (press release)

Whatever happened to the next big thing?  -  Apr 10, 2008
Its two cancer-fighting drugs, Campath and Velcade, came about the old-fashioned way: Millennium bought the smaller companies that developed the drugs. Boston Globe,

AAN: Monoclonal Antibodies Shine in Relapsing-Remitting MS but Not ...  -  Apr 17, 2008
April 17 -- Three monoclonal antibodies in development for relapsing-remitting multiple sclerosis show promise, but alemtuzumab (Campath) appears to be MedPage Today,

Takeda Takes Hold of Millenniium for $8.8 Billion  -  Apr 10, 2008
The biotech got hold of its first approved drug, Campath (now owned by Genzyme), and its one currently marketed product, the cancer drug Velcade, Xconomy,

Japanese Drug Company Bids for US Biotech Firm  -  Apr 11, 2008
It bought a company called LeukoSite mainly to obtain Campath, a cancer drug now sold by Genzyme. All but overlooked, at first, was another LeukoSite drug BlueRidgeNow.com,

Earnings Preview: Genzyme  -  Feb 11, 2008
The company also reported results from a midstage study, showing the drug Campath was more effective than Merck KGaA'a Rebif in treating multiple sclerosis. Houston Chronicle,

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year  -  Feb 13, 2008
...and Elaprase(R) (idursulfase) in Japan-and secured expanded US labeling for Campath(R) (alemtuzumab) and Thyrogen(R) (thyrotropin alfa for injection). SunHerald.com,

Genentech, Biogen's Rituxan Cuts Relapses of Multiple Sclerosis  -  Feb 14, 2008
...s Campath has shown a similar effect in clinical trials, he said. ``The real strength is the magnitude of effect on the MRI, the relapse rate, Bloomberg

Cytomegalovirus Infection in Paediatric Haemopoietic Stem Cell ...  -  Feb 26, 2008
The pan T-cell antibody Campath was incorporated into conditioning regimens for patients undergoing unrelated transplants. Three patients had ex vivo T-cell Irish Medical Journal,

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year  -  Feb 13, 2008
Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks PR Newswire (press release),

MabCampath Available For First Line Treatment Of B-Cell Chronic ...  -  Feb 19, 2008
The product was launched in its oncology indication in the US in June 2001, where it is marketed by Bayer HealthCare Pharmaceuticals Inc. as Campath®, Medical News Today (press release),

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year  -  Feb 14, 2008
...and Elaprase® (idursulfase) in Japan - and secured expanded US labeling for Campath® (alemtuzumab) and Thyrogen® (thyrotropin alfa for injection). Lifescience-online,

Bayer says MS drug a possible blockbuster  -  Jan 8, 2008
Alemtuzumab, which entered Bayer's pipeline through the acquisitions of Schering AG, is already approved for the treatment of leukemia as Campath. MarketWatch

BTG plc: Interim Management Statement  -  Jan 24, 2008
Momentum in our own development pipeline has been supplemented by progress in licensed programmes, including Campath® in CLL and MS, TRX4 in type 1 diabetes PharmaLive.com (press release),

Genzyme Tells It Like It Is  -  Feb 4, 2008
...also talked extensively about its multiple sclerosis (MS) treatment alemtuzumab, which is a formulation of the already approved leukemia drug Campath. Motley Fool

Bayer Schering Pharma Updated Company Profile: Outlook, Strategy ...  -  Jan 8, 2008
Competitive landscape 109 Oncology 111 Nexavar 111 Overview 111 Sales forecast 112 Newsflow 113 Competitive landscape 114 Campath 116 Overview 116 Sales Reuters

Premier treat for brave schoolgirl  -  Jan 24, 2008
She later became the only person under 18 to try out the trial MS drug Campath. Dad Bill said: “It was a really good day and we were treated so well. ChronicleLive,

Trends in Kidney Transplantation  -  Jan 15, 2008
Basiliximab, daclizumab, Campath 1H are used as induction immuno suppressives and they have decreased the acute rejection episodes. Express Healthcare Management,

Just got back home after an emergency appointment!!!  -  Jan 15, 2008
Its just a minor blip as to be expected with the campath. He is sending me for a MRI scan within the next month because he wants to know if there are any ChronicleLive,

Stem Cells May Gradually Replace Antirejection Drugs For Kidney ...  -  Jan 23, 2008
During this time the recipient is treated with Campath-1H, a potent antibody used extensively at Northwestern to prevent rejection, in addition to the other Science Daily (press release)

Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue  -  Jan 8, 2008
...the use of Campath(R) (alemtuzumab) as a first-line treatment for B-cell chronic lymphocytic leukemia, and the expansion of these products in markets FOX News

Checking in on Biogen  -  Jan 9, 2008
...of Tysabri and its potential competitors, including Genzyme's (Nasdaq: GENZ) Campath and Novartis' (NYSE: NVS) oral multiple sclerosis therapy FTY720. Motley Fool

Outlook 2008: BioTech Offers Investment Longevity  -  Jan 16, 2008
For instance, Campath, a drug originally intended to treat cancer, is also used to treat multiple sclerosis. Genzyme reported a 20% growth in revenue for Money Morning

High-profit products old and new keep Genzyme on the up  -  Jan 9, 2008
...driven by Clolar (clofarabine) as a first-line therapy for adult acute myeloid leukaemia and the use of Campath (alemtuzumab), partnered with Bayer, Pharma Times (subscription),

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.